Host Immunity and Immunization Strategies for Clostridioides difficile Infection.
Farha NazWilliam A PetriPublished in: Clinical microbiology reviews (2023)
Clostridioides difficile infection (CDI) represents a significant challenge to public health. C. difficile-associated mortality and morbidity have led the U.S. CDC to designate it as an urgent threat. Moreover, recurrence or relapses can occur in up to a third of CDI patients, due in part to antibiotics being the primary treatment for CDI and the major cause of the disease. In this review, we summarize the current knowledge of innate immune responses, adaptive immune responses, and the link between innate and adaptive immune responses of the host against CDI. The other major determinants of CDI, such as C. difficile toxins, the host microbiota, and related treatments, are also described. Finally, we discuss the known therapeutic approaches and the current status of immunization strategies for CDI, which might help to bridge the knowledge gap in the generation of therapy against CDI.
Keyphrases
- immune response
- clostridium difficile
- public health
- healthcare
- dendritic cells
- toll like receptor
- current status
- end stage renal disease
- ejection fraction
- newly diagnosed
- cell cycle
- cardiovascular disease
- peritoneal dialysis
- stem cells
- bone marrow
- combination therapy
- risk factors
- type diabetes
- replacement therapy
- prognostic factors
- coronary artery disease
- patient reported